Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour

Sara Elena Rebuzzi, Massimiliano Grassi, Fabio Catalano, Michele Buscaglia, Rossella Bertulli, Camilla Satragno, Liliana Belgioia, Danila Comandini

Research output: Contribution to journalArticle

Abstract

Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as 'pigmented villonodular (teno)synovitis' is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.

Original languageEnglish
Pages (from-to)80-84
Number of pages5
JournalAnti-Cancer Drugs
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1 2020

Fingerprint

Pigmented Villonodular Synovitis
Synovial Bursa
Therapeutics
Recurrence
Adjuvant Radiotherapy
Rare Diseases
Tendons
Protein-Tyrosine Kinases
Neoplasms
Joints
Giant Cell Tumor of Tendon Sheath
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Rebuzzi, S. E., Grassi, M., Catalano, F., Buscaglia, M., Bertulli, R., Satragno, C., ... Comandini, D. (2020). Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. Anti-Cancer Drugs, 31(1), 80-84. https://doi.org/10.1097/CAD.0000000000000844

Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. / Rebuzzi, Sara Elena; Grassi, Massimiliano; Catalano, Fabio; Buscaglia, Michele; Bertulli, Rossella; Satragno, Camilla; Belgioia, Liliana; Comandini, Danila.

In: Anti-Cancer Drugs, Vol. 31, No. 1, 01.01.2020, p. 80-84.

Research output: Contribution to journalArticle

Rebuzzi, SE, Grassi, M, Catalano, F, Buscaglia, M, Bertulli, R, Satragno, C, Belgioia, L & Comandini, D 2020, 'Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour', Anti-Cancer Drugs, vol. 31, no. 1, pp. 80-84. https://doi.org/10.1097/CAD.0000000000000844
Rebuzzi, Sara Elena ; Grassi, Massimiliano ; Catalano, Fabio ; Buscaglia, Michele ; Bertulli, Rossella ; Satragno, Camilla ; Belgioia, Liliana ; Comandini, Danila. / Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. In: Anti-Cancer Drugs. 2020 ; Vol. 31, No. 1. pp. 80-84.
@article{a0538c675c32480fa0daf458b48f59e5,
title = "Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour",
abstract = "Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as 'pigmented villonodular (teno)synovitis' is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.",
author = "Rebuzzi, {Sara Elena} and Massimiliano Grassi and Fabio Catalano and Michele Buscaglia and Rossella Bertulli and Camilla Satragno and Liliana Belgioia and Danila Comandini",
year = "2020",
month = "1",
day = "1",
doi = "10.1097/CAD.0000000000000844",
language = "English",
volume = "31",
pages = "80--84",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour

AU - Rebuzzi, Sara Elena

AU - Grassi, Massimiliano

AU - Catalano, Fabio

AU - Buscaglia, Michele

AU - Bertulli, Rossella

AU - Satragno, Camilla

AU - Belgioia, Liliana

AU - Comandini, Danila

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as 'pigmented villonodular (teno)synovitis' is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.

AB - Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as 'pigmented villonodular (teno)synovitis' is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.

UR - http://www.scopus.com/inward/record.url?scp=85075959497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075959497&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000844

DO - 10.1097/CAD.0000000000000844

M3 - Article

C2 - 31567307

AN - SCOPUS:85075959497

VL - 31

SP - 80

EP - 84

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 1

ER -